The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I get these vicious apus ulcers uh little mouth sores canker Source yes about 10% of people get them hm it's paradoxically the only biomarker we probably have so I I secretly uh rejoice in knowing that at least I'm getting a good batch of rap AIS by virtue of the side effect by virtue of these miserable side effects
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
On the toxicity of #rapamycin - and how to reduce mouth sores
well as you pointed out mouth ulcers are one of the more common and fairly specific side effects for rapid logs
I think I would argue it's sort of epithelia uh proliferating fast and and you're slowing it down and perhaps losing barrier function
that's the most common uh side effect that that organ transplant patients experience
I think I would argue it's sort of epithelia uh proliferating fast and you're slowing it down and perhaps losing barrier function
it's my only biomarker that I know that I'm getting high quality rapamycin
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.